Sequencing Systemic Therapies in Metastatic Castration-Resistant Prostate Cancer

Abstract

Background

Men with prostate cancer will not die of the disease until it progresses to the metastatic castration-resistant stage. At that stage, the median survival is 9 to 30 months.

Methods

Recently approved and emerging treatments for metastatic castration-resistant prostate cancer (mCRPC) were reviewed based on their mechanisms of action, as well as sequencing and combining these treatments with existing options.

Results

Advances in androgen deprivation therapy, immunotherapy, bone-targeted therapy, and chemotherapy have led to approvals of abiraterone acetate, sipuleucel-T, denosumab, and cabazitaxel for the treatment of mCRPC. Despite improvements in patient survival and quality of life, mCRPC remains incurable.

Conclusions

With the emerging new therapies, this is an unprecedented time in treating mCRPC. A better understanding of their mechanisms of action, the genetic makeup of each mCRPC, and the development of new prognostic and predictive biomarkers will help determine sequencing or different combination treatments for each individual patient.

References

Siegel

, Naishadham

, Jemal

. Cancer statistics, 2013. CA Cancer J Clin. 2013; 63(1): 11–30.

Kirby

, Hirst

, Crawford

E.D.

. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011; 65(11): 1180–1192.

Berthold

D.R.

, Sternberg

C.N.

, Tannock

I.F.

. Management of advanced prostate cancer after first-line chemotherapy. J Clin Oncol. 2005; 23(32): 8247–8252.

Massard

, Fizazi

. Targeting continued androgen receptor signaling in prostate cancer. Clin Cancer Res. 2011; 17(12): 3876–3883.

de Bono

J.S.

, Logothetis

C.J.

, Molina

. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011; 364(21): 1995–2005.

Scher

H.I.

, Fizazi

, Saad

. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012; 367(13): 1187–1197.

Attard

, Belldegrun

A.S.

, de Bono

J.S.

. Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int. 2005; 96(9): 1241–1246.

Barrie

S.E.

, Haynes

B.P.

, Potter

G.A.

. Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P450(17alpha) inhibitors. J Steroid Biochem Mol Biol. 1997; 60(5-6): 347–351.

Jarman

, Barrie

S.E.

, Llera

J.M.

. The 16,17-double bond is needed for irreversible inhibition of human cytochrome p45017alpha by abiraterone (17-(3-pyridyl)androsta-5,16-dien-3beta-ol) and related steroidal inhibitors. J Med Chem. 1998; 41(27): 5375–5381.

10.

Potter

G.A.

, Barrie

S.E.

, Jarman

. Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer. J Med Chem. 1995; 38(13): 2463–2471.

11.

Ryan

C.J.

, Smith

M.R.

, de Bono

J.S.

. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013; 368(2): 138–148.

12.

Dreicer

, Agus

D.B.

, MacVicar

G.R.

. Safety, pharmacokinetics, and efficacy of TAK-700 in metastatic castration-resistant prostrate cancer: a phase I/II, open-label study. J Clin Oncol. 2010; 28(15 suppl): 254s. Abstract 3084.

13.

Tran

, Ouk

, Clegg

N.J.

. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009; 324(5928): 787–790.

14.

Small

E.J.

, Fratesi

, Reese

D.M.

. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol. 2000; 18(23): 3894–3903.

15.

Burch

P.A.

, Breen

J.K.

, Buckner

J.C.

. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res. 2000; 6(6): 2175–2182.

16.

Goldstein

N.S.

. Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores. Am J Clin Pathol. 2002; 117(3): 471–477.

17.

Kantoff

P.W.

, Higano

C.S.

, Shore

N.D.

. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010; 363(5): 411–422.

18.

Higano

C.S.

, Schellhammer

P.F.

, Small

E.J.

. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009; 115(16): 3670–3679.

19.

Fong

, Small

E.J.

. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol. 2008; 26(32): 5275–5283.

20.

O'Day

S.J.

, Hamid

, Urba

W.J.

. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer. 2007; 110(12): 2614–2627.

21.

Robert

, Ghiringhelli

. What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma? Oncologist. 2009; 14(8): 848–861.

22.

Weber

. Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother. 2009; 58(5): 823–830.

23.

Hodi

F.S.

, O'Day

S.J.

, McDermott

D.F.

. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8): 711–723.

24.

Tollefson

M.K.

, Karnes

R.J.

, Thompson

R.H.

. A randomized phase II study of ipilimumab with androgen ablation compared with androgen ablation alone in patients with advanced prostate cancer. In: Program and abstracts of the American Society of Clinical Oncology 2010 Genitourinary Cancers Symposium; March 5-7, 2010; San Francisco, CA. Abstract 168.

25.

Kantoff

P.W.

, Schuetz

T.J.

, Blumenstein

B.A.

. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010; 28(7): 1099–1105.

26.

Petrylak

D.P.

, Tangen

C.M.

, Hussain

M.H.

. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004; 351(15): 1513–1520.

27.

Tannock

I.F.

, de Wit

, Berry

W.R.

. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351(15): 1502–1512.

28.

Kelly

W.K.

, Halabi

, Carducci

M.A.

. A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): survival results of CALGB 90401. J Clin Oncol. 2010; 28(18s). Abstract LBA4511.

29.

Celgene discontinues Revlimid prostate cancer trial. http://www.pharmatimes.com/Article/11-11-23/Celgene_discontinues_Revlimid_prostate_cancer_trial.aspx. Accessed April 11, 2013.

30.

Araujo

J.C.

, Trudel

G.C.

, Saad

. Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): results from the randomized phase III READY trial. Presented at the 2013 Genitourinary Cancers Symposium, February 14-16, 2013, Orlando, FL. J Clin Oncol. 2013; 31(6 Feb 20 suppl): LBA8. Abstract.

31.

de Bono

J.S.

, Oudard

, Ozguroglu

. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010; 376(9747): 1147–1154.

32.

Fleisch

. Bisphosphonates: mechanisms of action. Endocr Rev. 1998; 19(1): 80–100.

33.

Berenson

J.R.

, Rosen

L.S.

, Howell

. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer. 2001; 91(7): 1191–1200.

34.

Rosen

L.S.

, Gordon

, Kaminski

. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 2001; 7(5): 377–387.

35.

Saad

, Gleason

D.M.

, Murray

. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002; 94(19): 1458–1468.

36.

Boyle

W.J.

, Simonet

W.S.

, Lacey

D.L.

. Osteoclast differentiation and activation. Nature. 2003; 423(6937): 337–342.

37.

Fizazi

, Carducci

, Smith

. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011; 377(9768): 813–822.

38.

Smith

M.R.

, Saad

, Coleman

. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet. 2012; 379(9810): 39–46.

39.

Bauman

, Charette

, Reid

. Radiopharmaceuticals for the palliation of painful bone metastasis-a systemic review. Radiother Oncol. 2005; 75(3): 258–270.

40.

Parker

, Heinrich

, O'Sullivan

J.M.

. Overall survival benefit of radium-223 chloride (Alpharadin) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer (CRPC): a phase III randomised trial (ALSYMPCA). Eur J Cancer. 2011; 47(suppl 2). Abstract 1LBA.

41.

Bubendorf

, Schopfer

, Wagner

, Sauter

, Moch

, Willi

, Gasser

T.C.

, Mihatsch

M.J.

. Metastatic patterns of prostate cancer: An autopsy study of 1,589 patients. Hum. Pathol. 2000; 31: 578–583.